title: Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure.
abstract: BACKGROUND
  FV inhibitors are a largely preventable iatrogenic coagulopathy in which the frequency is increasing in clinical practice.
  
  
  METHODS
  Three cases associated with our institution are reported. A systematic review of the MEDLINE database was performed, and reference lists were reviewed to identify relevant publications.
  
  
  RESULTS
  One hundred twenty-six cases of FV inhibitors have been reported in the world's literature. Eighty-seven have been reported in the last decade, of which two thirds are due to exposure to bovine thrombin. Bovine thrombin-associated FV antibodies develop in 40 to 66 percent of cardiac surgery patients and in 20 percent of neurosurgery patients. Thirty-three percent of reported patients developed bleeding complications. Inhibitors persisted on average 2.3 months. Standard coagulation assays do not reliably predict clinical manifestations. Multimodality therapy, including immunosuppression, is useful for treatment of symptomatic patients.
  
  
  CONCLUSIONS
  FV inhibitors are a common complication of bovine thrombin exposure that can have devastating clinical consequences. Transfusion medicine specialists and hematologists can play a critical role in reducing the incidence of FV inhibitors by educating the medical community about safer alternative fibrin sealants.
authors.affiliation: Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA. mstreif@jhmi.edu
authors.forename: Michael B
authors.initials: MB
authors.lastname: Streiff
authors.forename: Paul M
authors.initials: PM
authors.lastname: Ness
mesh_terms: D000368:Aged; D000818:Animals; D000910:Antibodies, Heterophile / Q000096:biosynthesis*; D000918:Antibody Specificity; D001024:Aortic Valve Stenosis / Q000601:surgery; D020517:Atrial Appendage; D001281:Atrial Fibrillation / Q000150:complications; D001780:Blood Coagulation Tests; D002417:Cattle; D001026:Coronary Artery Bypass; D005165:Factor V / Q000276:immunology*; D005166:Factor V Deficiency / Q000139:chemically induced*; D015718:Fibrin Tissue Adhesive / Q000009:adverse effects* / Q000276:immunology; D006333:Heart Failure / Q000209:etiology / Q000601:surgery; D019918:Heart Valve Prosthesis Implantation; D006488:Hemostasis, Surgical / Q000009:adverse effects; D006801:Humans; D007049:Iatrogenic Disease; D007430:Intraoperative Care; D008297:Male; D009203:Myocardial Infarction / Q000150:complications; D010314:Partial Thromboplastin Time; D010641:Phenotype; D011183:Postoperative Complications / Q000209:etiology; D013917:Thrombin / Q000009:adverse effects* / Q000276:immunology; D013927:Thrombosis / Q000209:etiology
chemical_list: D000910:Antibodies, Heterophile; D015718:Fibrin Tissue Adhesive; D005165:Factor V; D013917:Thrombin